The objective of this study was to evaluate the stability of estrone (0.1-1%), estradiol (0.05-2%), estriol (0.05-2%), progesterone ( 0.1-20%), testosterone (0.1-20%), combination (estradiol 0.05%, estriol 0.05%, progesterone 0.5%), and combination (estradiol 2%, estriol 1%, progesterone 20%). The beyond-use date was 180 days in all samples except estrone (150 days).

The study describes the cases of four COVID-19 patients that used a combination of Imuno TF®, Miodesin®, and SiliciuMax® for improvement of their symptoms. The four showed improvement in general symptoms after treatment, representing a good starting point to further investigate this possible add-on therapy in controlled clinical studies.

The study followed the progression of COVID-19 in patients treated with ImmunoFormulation (IF) versus untreated patients. Throughout the observational period, 90% of patients recovered in the IF cohort (47.4% in the Control cohort). Symptom duration was shorter in the IF cohort, especially for fever, dry cough, dyspnoea, diarrhoea, and weakness.

This review gives the scientific background on the hypothesis that Imuno TF®, Miodesin®, and SiliciuMax® can act in synergy in the prevention and improvement of COVID-19-associated symptoms.

The study evaluated the effect of Imuno TF® on the immune system. Th1 cytokines were upregulated, while decreasing Th2 cytokines. mRNA and anti-inflammatory cytokine IL-10 levels increased, whereas mRNA and pro-inflammatory cytokines IL-6 and TNF-α were reduced. Finally, it reversed IL-17 hypersecretion and did not alter IL-35 secretion.

This case study describes a patient with periungual warts (PW) resistant to a range of standard treatments. His clinical condition dramatically improved after use of isolated transfer factors (TF). As shown in this case, TF could be a possible effective alternative to treat therapy-resistant PW.

The study investigated the content uniformity of a wide range of different active pharmaceutical ingredients (APIs) in SyrSpend SF, and compared with what is known for the content uniformity of extemporaneous prepared capsules. Compounded oral liquids in SyrSpend SF showed little content variation, and were well within the criteria defined.

The objective of this study was to evaluate the stability of oral suspensions compounded with SyrSpend SF PH4 and commonly used active pharmaceutical ingredients (APIs). Formulations using the API in powder form presented a higher beyond-use date, and SyrSpend SF PH4 shows suitability for compounding APIs from different pharmacological classes.

Analyses with SyrSpend SF in 104 different formulations with 89 unique active pharmaceutical ingredients showed results that all 6.414 samples analyzed were within specification. The results suggest that SyrSpend SF could be a better way to assure content uniformity compared to manually compounded, small-batch extemporaneous capsules.

The study aimed to investigate the effect of Trichoxidil in the treatment of hair loss caused by androgenetic alopecia (AGA). Trichoxidil promoted proliferative effects and positively modulated the expression of growth factors IGF-1, VEGF, and KGF, being a promising candidate for the treatment of hair loss caused by AGA.